LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

NVS

153.4

+3.33%↑

Search

TransMedics Group Inc

Fechado

SetorSaúde

73.67 -2.19

Visão Geral

Variação de preço das ações

24h

Atual

Mín

72.59

Máximo

75.5

Indicadores-chave

By Trading Economics

Rendimento

-98M

7.3M

Vendas

13M

174M

P/E

Médio do Setor

17.279

49.712

EPS

0.3

Margem de lucro

4.206

Funcionários

898

EBITDA

-4.9M

28M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+59.25% upside

Dividendos

By Acuity

Próximos Ganhos

29 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-744M

2.6B

Abertura anterior

75.86

Fecho anterior

73.67

Sentimento de Notícias

By Acuity

50%

50%

128 / 342 Ranking em Healthcare

TransMedics Group Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Sobre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat